Do analysts prefer CUE or CADL?

Candel Therapeutics has a consensus target price of $19.29, indicating a potential upside of 73.43%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Candel Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Does the media favor CUE or CADL?

In the previous week, Candel Therapeutics had 4 more articles in the media than Cue Biopharma. MarketBeat recorded 8 mentions for Candel Therapeutics and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.84 beat Candel Therapeutics' score of 0.82 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Candel Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SLN or CUE?

Silence Therapeutics currently has a consensus target price of $53.50, suggesting a potential upside of 329.37%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to SLN or CUE?

In the previous week, Cue Biopharma had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 4 mentions for Cue Biopharma and 2 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.87 beat Cue Biopharma's score of 1.84 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cue Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer CUE or PHAR?

Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 266.51%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pharming Group 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media favor CUE or PHAR?

In the previous week, Pharming Group had 11 more articles in the media than Cue Biopharma. MarketBeat recorded 15 mentions for Pharming Group and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.84 beat Pharming Group's score of 0.90 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Pharming Group 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CUE or DBVT?

DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 312.41%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DBV Technologies 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media refer more to CUE or DBVT?

In the previous week, Cue Biopharma had 1 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Cue Biopharma and 3 mentions for DBV Technologies. Cue Biopharma's average media sentiment score of 1.84 beat DBV Technologies' score of 1.07 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NVCT or CUE?

Nuvectis Pharma currently has a consensus target price of $36.25, indicating a potential upside of 65.37%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to NVCT or CUE?

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 4 articles in the media. Cue Biopharma's average media sentiment score of 1.84 beat Nuvectis Pharma's score of 0.62 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cue Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Cue Biopharma (CUE) Competitors

$31.64 +1.09 (+3.57%)

Closing price 04:00 PM Eastern

Extended Trading

$30.72 -0.93 (-2.92%)

As of 06:49 PM Eastern

Compare

CUE vs. CADL, SLN, PHAR, DBVT, and NVCT

Should you buy Cue Biopharma stock or one of its competitors? Cue Biopharma's main competitors and comparable companies include Candel Therapeutics (CADL), Silence Therapeutics (SLN), Pharming Group (PHAR), DBV Technologies (DBVT), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cue Biopharma compare to Candel Therapeutics?

Cue Biopharma (NASDAQ:CUE) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cue Biopharma has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.48, suggesting that its share price is 148% less volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Candel Therapeutics' return on equity of -76.98% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Candel Therapeutics	N/A	-76.98%	-48.50%

Cue Biopharma has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	8.36	-$26.60M	-$27.02	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Candel Therapeutics has a consensus target price of $19.29, indicating a potential upside of 73.43%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Candel Therapeutics had 4 more articles in the media than Cue Biopharma. MarketBeat recorded 8 mentions for Candel Therapeutics and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.84 beat Candel Therapeutics' score of 0.82 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Candel Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Candel Therapeutics beats Cue Biopharma on 8 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

In the previous week, Cue Biopharma had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 4 mentions for Cue Biopharma and 2 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.87 beat Cue Biopharma's score of 1.84 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cue Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cue Biopharma has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$615K	1,219.84	-$88.61M	-$1.28	N/A
Cue Biopharma	$27.47M	8.36	-$26.60M	-$27.02	N/A

Cue Biopharma has a net margin of -435.83% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -106.94% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Cue Biopharma	-435.83%	-620.06%	-291.15%

Silence Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Silence Therapeutics currently has a consensus target price of $53.50, suggesting a potential upside of 329.37%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Silence Therapeutics beats Cue Biopharma on 10 of the 17 factors compared between the two stocks.

How does Cue Biopharma compare to Pharming Group?

Cue Biopharma (NASDAQ:CUE) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Pharming Group has a consensus target price of $38.67, suggesting a potential upside of 266.51%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pharming Group has higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	8.36	-$26.60M	-$27.02	N/A
Pharming Group	$366.48M	2.04	$2.85M	$0.12	87.92

In the previous week, Pharming Group had 11 more articles in the media than Cue Biopharma. MarketBeat recorded 15 mentions for Pharming Group and 4 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.84 beat Pharming Group's score of 0.90 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pharming Group	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pharming Group has a net margin of 2.51% compared to Cue Biopharma's net margin of -435.83%. Pharming Group's return on equity of 3.40% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Pharming Group	2.51%	3.40%	1.90%

Summary

Pharming Group beats Cue Biopharma on 11 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to DBV Technologies?

Cue Biopharma (NASDAQ:CUE) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 312.41%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Cue Biopharma has a net margin of -435.83% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Cue Biopharma has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	8.36	-$26.60M	-$27.02	N/A
DBV Technologies	$5.64M	131.11	-$146.95M	-$3.51	N/A

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cue Biopharma had 1 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Cue Biopharma and 3 mentions for DBV Technologies. Cue Biopharma's average media sentiment score of 1.84 beat DBV Technologies' score of 1.07 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, indicating that its share price is 195% less volatile than the broader market.

Summary

Cue Biopharma and DBV Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Nuvectis Pharma currently has a consensus target price of $36.25, indicating a potential upside of 65.37%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 28.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 4 articles in the media. Cue Biopharma's average media sentiment score of 1.84 beat Nuvectis Pharma's score of 0.62 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cue Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Nuvectis Pharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Nuvectis Pharma's return on equity of -184.25% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Cue Biopharma	-435.83%	-620.06%	-291.15%

Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market.

Nuvectis Pharma has higher earnings, but lower revenue than Cue Biopharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Cue Biopharma	$27.47M	8.36	-$26.60M	-$27.02	N/A

Summary

Nuvectis Pharma beats Cue Biopharma on 11 of the 15 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$229.71M	$3.83B	$7.16B	$14.34B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-1.17	14.18	273.41	25.34
Price / Sales	8.36	1,542.12	674.92	98.63
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	3.14	15.19	10.38	6.20
Net Income	-$26.60M	-$22.78M	$3.49B	$358.18M
7 Day Performance	5.47%	-2.55%	-2.20%	-1.61%
1 Month Performance	-7.49%	0.29%	-0.38%	-3.62%
1 Year Performance	-95.25%	39.29%	19.16%	5.95%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	1.0167 of 5 stars	$31.64 +3.6%	N/A	-95.4%	$229.71M	$27.47M	N/A	29	Positive News
CADL Candel Therapeutics	3.312 of 5 stars	$10.37 -8.5%	$19.29 +86.0%	+123.0%	$792.98M	N/A	N/A	60
SLN Silence Therapeutics	3.3584 of 5 stars	$13.13 -1.4%	$53.50 +307.6%	+189.6%	$790.26M	$560K	N/A	100	Positive News
PHAR Pharming Group	4.4861 of 5 stars	$11.11 +2.7%	$38.67 +248.2%	-26.3%	$786.01M	$376.13M	92.54	280	News Coverage Analyst Forecast Short Interest Decrease Analyst Revision
DBVT DBV Technologies	3.4585 of 5 stars	$12.08 -6.8%	$48.50 +301.4%	+25.1%	$770.53M	N/A	N/A	80	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. CADL, SLN, PHAR, DBVT, and NVCT

How does Cue Biopharma compare to Candel Therapeutics?

Summary

How does Cue Biopharma compare to Silence Therapeutics?

Summary

How does Cue Biopharma compare to Pharming Group?

Summary

How does Cue Biopharma compare to DBV Technologies?

Summary

How does Cue Biopharma compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. CADL, SLN, PHAR, DBVT, and NVCT

How does Cue Biopharma compare to Candel Therapeutics?

Do institutionals and insiders believe in CUE or CADL?

Which has more risk and volatility, CUE or CADL?

Is CUE or CADL more profitable?

Which has better valuation & earnings, CUE or CADL?

Do analysts prefer CUE or CADL?

Does the media favor CUE or CADL?

Summary

How does Cue Biopharma compare to Silence Therapeutics?

Does the media refer more to SLN or CUE?

Which has stronger valuation and earnings, SLN or CUE?

Is SLN or CUE more profitable?

Which has more risk and volatility, SLN or CUE?

Do institutionals & insiders hold more shares of SLN or CUE?

Do analysts recommend SLN or CUE?

Summary

How does Cue Biopharma compare to Pharming Group?

Do analysts prefer CUE or PHAR?

Which has preferable earnings and valuation, CUE or PHAR?

Does the media favor CUE or PHAR?

Which has more volatility and risk, CUE or PHAR?

Do institutionals & insiders have more ownership in CUE or PHAR?

Is CUE or PHAR more profitable?

Summary

How does Cue Biopharma compare to DBV Technologies?

Do analysts recommend CUE or DBVT?

Is CUE or DBVT more profitable?

Which has preferable valuation & earnings, CUE or DBVT?

Do institutionals & insiders believe in CUE or DBVT?

Does the media refer more to CUE or DBVT?

Which has more volatility & risk, CUE or DBVT?

Summary

How does Cue Biopharma compare to Nuvectis Pharma?

Do analysts prefer NVCT or CUE?

Do insiders & institutionals believe in NVCT or CUE?

Does the media refer more to NVCT or CUE?

Is NVCT or CUE more profitable?

Which has more risk and volatility, NVCT or CUE?

Which has stronger valuation and earnings, NVCT or CUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools